Bispecific Antibody Affords Complete Post-Exposure Protection of Mice from Both Ebola (Zaire) and Sudan Viruses
Autor: | Kartik Chandran, Julia C. Frei, Russell R. Bakken, Samantha E. Zak, Elisabeth K. Nyakatura, John M. Dye, Jonathan R. Lai |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2016 |
Předmět: |
0301 basic medicine
Bispecific antibody Post exposure Antibody Affinity Cross Reactions medicine.disease_cause Antibodies Viral Protein Engineering Epitope Neutralization Article Cell Line 03 medical and health sciences Mice Neutralization Tests Antibodies Bispecific Medicine Animals Humans Ebolavirus chemistry.chemical_classification Multidisciplinary biology business.industry Outbreak Hemorrhagic Fever Ebola Virology Antibodies Neutralizing 3. Good health Disease Models Animal 030104 developmental biology chemistry biology.protein Antibody business Glycoprotein Post-Exposure Prophylaxis Protein Binding |
Zdroj: | Scientific Reports |
ISSN: | 2045-2322 |
Popis: | Filoviruses (Ebola and Marburg) cause severe hemorrhagic fever. There are five species of ebolavirus; among these, the Ebola (Zaire) and Sudan viruses (EBOV and SUDV, respectively) are highly pathogenic and have both caused recurring, large outbreaks. However, the EBOV and SUDV glycoprotein (GP) sequences are 45% divergent and thus antigenically distinct. Few antibodies with cross-neutralizing properties have been described to date. We used antibody engineering to develop novel bispecific antibodies (Bis-mAbs) that are cross-reactive toward base epitopes on GP from EBOV and SUDV. These Bis-mAbs exhibit potent neutralization against EBOV and SUDV GP pseudotyped viruses as well as authentic pathogens and confer a high degree (in one case 100%) post-exposure protection of mice from both viruses. Our studies show that a single agent that targets the GP base epitopes is sufficient for protection in mice; such agents could be included in panfilovirus therapeutic antibody cocktails. |
Databáze: | OpenAIRE |
Externí odkaz: |